Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
February 20 2024 - 3:27PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of February 2024 (Report No.2)
Commission file number: 001-38041
SCISPARC LTD.
(Translation of registrant’s name into English)
20 Raul Wallenberg Street, Tower A,
Tel Aviv 6971916 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
CONTENTS
On February 20, 2024,
SciSparc Ltd. (the “Company”) issued a press release titled “SciSparc and Clearmind Continue to Strengthen
International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds.” A copy of this press release is
furnished herewith as Exhibit 99.1 and incorporated by reference herein.
The press release furnished
as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s registration
statements on Form F-3 (File No. 333-275305, File No. 333-269839, File No. 333-266047, File No. 333-233417, File No. 333-248670, File
No. 333-255408, and File No. 333-275305) and on Form S-8 (File No. 333-225773) filed with the Securities and Exchange Commission to be
a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed
or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
SciSparc Ltd. |
|
|
|
Date: February 20, 2024 |
By: |
/s/ Oz Adler |
|
Name: |
Oz Adler |
|
Title: |
Chief Executive Officer and Chief Financial Officer |
3
Exhibit 99.1
SciSparc
and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based
Compounds
TEL
AVIV, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty
clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous
system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND)
(CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve
major under-treated mental health problems, Clearmind filed three patent applications under the international Patent Cooperation Treaty.
The
three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine
(DMT) and Palmitoylethanolamide (PEA), the active ingredient of SciSparc’s proprietary CannAmide™.
These
applications were previously filed by Clearmind as provisional patent applications with the United States Patent and Trademark Office.
“We
are pleased to continue our ongoing collaboration with Clearmind by expanding the intellectual property portfolio, which is an important
asset,” said SciSparc’s Chief Executive Officer, Oz Adler. “We believe in the added value that CannAmide™ can offer
when combined with various psychedelic compounds that are known for their therapeutics advantages.”
About SciSparc Ltd.
(Nasdaq: SPRC):
SciSparc
Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s
focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the
Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment
of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the
treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale
of hemp seeds oil-based products on the Amazon.com Marketplace.
Forward-Looking
Statements:
This
press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses
the Company’s ongoing collaboration with Clearmind and the belief of the added value that CannAmide™ can offer when combined
with various psychedelic compounds. Historical results of scientific research and clinical and preclinical trials do not guarantee that
the conclusions of future research or trials will suggest identical or even similar conclusions. Because such statements deal with future
events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance
or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking
statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the
heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the SEC on May 1, 2023, and in subsequent filings
with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation
to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information,
future events or circumstances or otherwise.
Investor
Contact:
IR@scisparc.com
Tel: +972-3-6167055
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Apr 2024 to May 2024
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From May 2023 to May 2024